ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Bayer is teaming up with the start-up NextRNA Therapeutics to develop two small-molecule drugs for unspecified cancers. Both programs will target long noncoding RNAs, a type of RNA that doesn’t code for proteins but instead interacts with them and modulates their activity. Bayer will pay NextRNA up to $547 million in up-front and milestone payments.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X